NIH #2P30CA023100-38
Protocol Review and Monitoring System
- Amount
- $162K
- Period
- 1996-07-01 → 2031-04-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF CALIFORNIA, SAN DIEGO
Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine
4 total · 1 active
NIH #2P30CA023100-38
Awarded at UNIVERSITY OF CALIFORNIA, SAN DIEGO
NIH #3P30CA023100-37S2
Awarded at UNIVERSITY OF CALIFORNIA, SAN DIEGO
NIH #5R43CA163436-02
Awarded at NANOCELLECT BIOMEDICAL, INC.
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
Circulating Biomarkers and Targeted Therapy in Pleural Mesothelioma
Cancers · 2025-12-01 · 1 citations
Journal of Thoracic Oncology · 2025-10-01 · 3 citations
Journal of Clinical Oncology · 2025-09-09 · 14 citations
Lung Cancer · 2025-09-07 · 4 citations
Annals of Oncology · 2025-09-01
Neuro-Oncology Advances · 2025-08-01
Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC)
Expert Opinion on Pharmacotherapy · 2025-07-23 · 1 citations
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2025.1 Part 1
2025-07-17
Journal of Clinical Oncology · 2025-07-17 · 7 citations
Journal of Clinical Oncology · 2025-07-09 · 21 citations
Value in Health · 2025-07-01
Clinical Lung Cancer · 2025-06-05 · 1 citations
Journal of Clinical Oncology · 2025-05-28 · 2 citations
Journal of Clinical Oncology · 2025-05-28 · 4 citations
Cell Reports Medicine · 2025-05-01 · 4 citations
Cancer Research · 2025-04-21
Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST
Journal of Clinical Oncology · 2025-04-03 · 46 citations
Future Oncology · 2025-03-28 · 2 citations
Journal of Thoracic Oncology · 2025-03-01 · 2 citations
Journal of Clinical Oncology · 2025-02-27 · 14 citations